Pfizer: initiates study in Lyme disease
(CercleFinance.com) - Valneva and Pfizer announce the initiation of the randomized Phase 2 trial VLA15-221 for their Lyme disease vaccine candidate, the first clinical study of VLA15 to include a pediatric population aged 5 to 17 years.
Approximately 600 healthy volunteers (aged 5 to 65 years) are expected to receive either VLA15 or a placebo. The study will compare a three-dose vaccination regimen (injected at zero, two and six months) and a two-dose vaccination regimen (injected at 0 and six months).
Valneva and Pfizer signed a collaboration agreement in April 2020 to joinly develop and market VLA15. According to the agreement, the vaccination of the first participant in the VLA15-221 study will trigger a 10 million dollar payment by Pfizer to Valneva.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Approximately 600 healthy volunteers (aged 5 to 65 years) are expected to receive either VLA15 or a placebo. The study will compare a three-dose vaccination regimen (injected at zero, two and six months) and a two-dose vaccination regimen (injected at 0 and six months).
Valneva and Pfizer signed a collaboration agreement in April 2020 to joinly develop and market VLA15. According to the agreement, the vaccination of the first participant in the VLA15-221 study will trigger a 10 million dollar payment by Pfizer to Valneva.
Copyright (c) 2021 CercleFinance.com. All rights reserved.